GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. The firm is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The firm also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The firm also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).
The most recent EPS for GSK plc is $0.46, beating expectations of $0.44.
How did GSK plc GSK's revenue perform in the last quarter?
GSK plc revenue for the last quarter is $0.46
What is the revenue estimate for GSK plc?
According to 10 of Wall street analyst, the revenue estimate of GSK plc range from $8.89B to $7.98B
What's the earning quality score for GSK plc?
GSK plc has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does GSK plc report earnings?
GSK plc next earnings report is expected in 2026-07-28
What are GSK plc's expected earnings?
GSK plc expected earnings is $7.81B, according to wall-street analysts.
Did GSK plc beat earnings expectations?
GSK plc recent earnings of $7.62B does not beat expectations.